Aegis Capital Corp.

In a report published Wednesday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Buy rating and $180.00 price target on Valeant Pharmaceuticals (NYSE: VRX). In the report, Aegis Capital Corp. noted, “Recently, Valeant's hedge fund partner Pershing Square Capital Management disclosed...

In a report published Wednesday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Buy rating and $125.00 price target on Medivation (NASDAQ: MDVN). In the report, Aegis Capital Corp. noted, “Early this morning, the Swiss pharmaceutical giant Roche (ROG/VTX, Not Rated) announced a massive...

In a report published Tuesday, Aegis Capital analyst Raghuram Selvaraju initiated coverage on Evoke Pharma (NASDAQ: EVOK) with a Buy rating and $60.00 price target. In the report, Aegis Capital Corp. noted, “We are initiating coverage on Evoke Pharma, Inc. with a Buy rating and an 18-month price...

In a report published Friday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Buy rating and $10.00 price target on TrovaGene (NASDAQ: TROV). In the report, Aegis Capital Corp. noted, “Yesterday afternoon, following the market close, Trovagene reported financial results for the third...

In a report published Thursday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Buy rating on Cancer Genetics (NASDAQ: CGIX), and raised the price target from $25.00 to $32.50. In the report, Aegis Capital Corp. noted, “Yesterday afternoon, after the market close, Cancer Genetics...

In a report published Thursday, Aegis Capital Corp. analyst Jayanta Datta initiated coverage on QLogic Corporation (NASDAQ: QLGC) with a Buy rating and $15.00 price target. In the report, Aegis Capital Corp. noted, “QLogic is a highly profitable market leader in the server and storage connectivity...

In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and $23.00 price target on Synergy Pharmaceuticals (NASDAQ: SGYP). In the report, Aegis Capital noted, “Yesterday, Synergy Pharmaceuticals reported results for 3Q 2013. The firm lost $0.15 per share...

In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and $100.00 price target on Medivation (NASDAQ: MDVN). In the report, Aegis Capital noted, “Yesterday afternoon, after the market close, Medivation released financial results for the third quarter of...

In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and $70.00 price target on Stemline Therapeutics (NASDAQ: STML). In the report, Aegis Capital noted, “We would guide investors to focus on the upcoming American Society for Hematology (ASH) Annual...

In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on TrovaGene (NASDAQ: TROV), but lowered the price target from $14.00 to $10.00. In the report, Aegis Capital noted, “In advance of Trovagene's earnings report due out later this week, we have revised...

In a report published Wednesday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Hold rating and $2.50 price target on Inovio Pharmaceuticals (NYSE: INO). In the report, Aegis Capital Corp. noted, “Yesterday, Inovio Pharmaceuticals reported financial results for the quarter ended...

In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Hold rating on Navidea Biopharmaceuticals (NYSE: NAVB), but lowered the price target from $3.00 to $2.00. In the report, Aegis Capital Corp. noted, “Last week, Navidea Biopharmaceuticals reported 3Q 2013...

In a report published Wednesday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and $7.00 price target on Sinovac Biotech (NASDAQ: SVA). In the report, Aegis Capital Corp. noted, “Yesterday after the market close, Sinovac Biotech announced its 3Q 2013 financial results. Total...

In a report published Wednesday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Hold rating on Amarin Corporation plc (NASDAQ: AMRN). In the report, Aegis Capital Corp. noted, “Yesterday, Amarin disclosed via 8-K filing that the FDA had notified it of the formal rescinding of the...